BRIEF published on 12/11/2025 at 07:05, 11 days 12 hours ago BioVersys lance un essai de phase 3 pour le BV100 et fait le point sur ses progrès commerciaux. Introduction En Bourse BioVersys Résistance Aux Médicaments BV100 Phase 3 Recherche Antibactérienne
BRIEF published on 12/11/2025 at 07:05, 11 days 12 hours ago BioVersys Initiates Phase 3 Trial for BV100 and Updates Business Progress IPO Drug Resistance BioVersys BV100 Phase 3 Antibacterial Research
PRESS RELEASE published on 12/11/2025 at 07:00, 11 days 12 hours ago BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update BioVersys AG initiates BV100 Phase 3 study for ventilator-associated bacterial pneumonia, achieving significant milestones in 2025 and upcoming key events in 2026 Clinical Trials Biopharmaceutical BioVersys AG BV100 Phase 3 Ventilator Associated Bacterial Pneumonia
BRIEF published on 11/10/2025 at 07:05, 1 month 12 days ago L'étude de phase 2B BV100 de BioVersys est prévue pour l'Asie Essai De Phase 2b Résistance Aux Médicaments BioVersys BV100 Financement Wellcome Réseau ADVANCE-ID
BRIEF published on 11/10/2025 at 07:05, 1 month 12 days ago BioVersys' BV100 Phase 2B Study Set for Asia Phase 2B Trial Drug Resistance BioVersys BV100 Wellcome Funding ADVANCE-ID Network
PRESS RELEASE published on 11/10/2025 at 07:00, 1 month 12 days ago BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network. BioVersys AG leads Phase 2 trial for innovative antibacterial product BV100 Phase 2b Clinical Trial BV100 BioVersys Wellcome Funded Trial Network
BRIEF published on 11/06/2025 at 07:05, 1 month 16 days ago BioVersys Advances BV100 Clinical Trials in China Clinical Trials BV100 BioVersys MDR Bacteria Acinetobacter
BRIEF published on 11/06/2025 at 07:05, 1 month 16 days ago BioVersys fait progresser les essais cliniques du BV100 en Chine Essais Cliniques BV100 BioVersys Bactéries Multirésistantes Acinetobacter
PRESS RELEASE published on 11/06/2025 at 07:00, 1 month 16 days ago Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA BioVersys announces the dosing of the first subject in a Phase 1 clinical trial with BV100 in China. BV100 targets MDR hospital infections caused by Acinetobacter baumannii Phase 1 Clinical Trial BV100 BioVersys MDR Bacteria Acinetobacter Baumannii
BRIEF published on 11/05/2025 at 07:05, 1 month 17 days ago BioVersys to Present at Stifel 2025 Annual Healthcare Conference New York City Healthcare Conference Clinical Developments BioVersys Multi-drug Resistant Bacteria
Published on 12/22/2025 at 15:00, 4 hours 51 minutes ago World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Published on 12/22/2025 at 14:40, 5 hours 11 minutes ago Namibia Critical Metals Inc. Receives Proceeds of $1,154,762 from Exercise of Warrants
Published on 12/22/2025 at 14:30, 5 hours 21 minutes ago Prospect Ridge Updates Diamond Drill Program at 100% Owned Camelot Copper-Gold Project in B.C.'S Cariboo Mining District
Published on 12/22/2025 at 14:00, 5 hours 51 minutes ago Rio Grande Resources Completes 2025 Field Program and Advances Drill Targeting at the Winston Gold-Silver Project
Published on 12/22/2025 at 14:00, 5 hours 51 minutes ago PPX Mining Appoints Ernest Mast as President and CEO and Announces Stock Option Grants
Published on 12/22/2025 at 19:31, 20 minutes ago EQS-Adhoc: Marley Spoon Group SE: CEO Daniel Raab Re-appointed and Contract to be Extended until June 2029
Published on 12/22/2025 at 19:00, 51 minutes ago PATRIMOINE ET COMMERCE: Déclarations des transactions sur actions propres (hors contrat de liquidité) réalisées le 19 décembre 2025
Published on 12/22/2025 at 18:51, 59 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 12/22/2025 at 18:20, 1 hour 31 minutes ago CGTN: How China drives high-quality development through technological innovation
Published on 12/22/2025 at 18:14, 1 hour 36 minutes ago Alzchem Group AG paves the way for continuity and further growth: Management Board contracts of Andreas Niedermaier and Andreas Lösler extended ahead of schedule
Published on 12/22/2025 at 18:33, 1 hour 18 minutes ago ABEO SE RENFORCE ET OBTIENT UNE TRÈS LARGE MAJORITÉ DU CAPITAL DE VOGO AVEC 90,84% DÉTENUS À L’ISSUE DE L’OFFRE RÉOUVERTE
Published on 12/22/2025 at 18:05, 1 hour 46 minutes ago Covivio - Treasury shares transactions between December 15th , 2025 and December 19th, 2025
Published on 12/22/2025 at 18:05, 1 hour 46 minutes ago Covivio - Déclaration des transactions sur actions propres réalisées du 15 décembre au 19 décembre 2025
Published on 12/22/2025 at 17:45, 2 hours 6 minutes ago Déclaration des transactions sur actions propres réalisées du 15 au 19 décembre 2025 dans le cadre du programme de rachat d’actions
Published on 12/22/2025 at 17:35, 2 hours 16 minutes ago DECLARATION HEBDOMADAIRE D'OPERATIONS EFFECTUEES DU 15 AU 19 DECEMBRE 2025
